<DOC>
	<DOCNO>NCT01236404</DOCNO>
	<brief_summary>Primary objective : To evaluate safety tolerability single multiple ascend dos PB1023 administer subcutaneous ( SC ) injection adult subject T2DM . Secondary objective : 1 . To characterize pharmacokinetic profile PB1023 single multiple ascend dos PB1023 . 2 . To assess pharmacodynamic response various single multiple dos PB1023 ( daily fast plasma glucose , serial glucose , c-peptide insulin level response liquid Mixed Meal Tolerance Test ( MMTT ) .</brief_summary>
	<brief_title>Phase 1/2a , Randomized , Double-Blind , Placebo-Controlled , Study Assess Safety , Tolerability , PK PD Response PB1023 Injection Following Single Multiple SQ Doses Adults With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males post menopausal surgically sterile female age 1875 year age inclusive . Diagnosed T2DM &gt; = 6 month HbA1c &gt; = 6.0 % &lt; = 9.0 % take stable dos one oral antihyperglycemic agent &lt; = 8.5 % take two oral antihyperglycemic agent maximum 3 month prior screen . Fasting Plasma glucose 115 mg/dL 269 mg/dL . Fasting Cpeptide &gt; = 0.8 ng/mL . BMI &lt; = 40 kg/m2 . Otherwise stable health except T2DM . Currently take nonoral antihyperglycemic agent . Have take PPARg agonist within 90 day screen . Known allergy approve investigational GLP1 receptor analog/agonist . Unstable cardiovascular disease define clinical protocol . History , symptoms sign pancreatitis severe gastrointestinal disease . Personal family history medullary thyroid tumor history Multiple Endocrine Neoplasia Syndrome Type 2 . Poor glucose control define clinical protocol . Clinically significant renal and/or hepatic dysfunction define clinical protocol . Absolute requirement corticosteroid receive systemic steroid within 90 day prior PB1023 administration . Pregnant lactating female . Known history active alcohol drug abuse within 12 month prior screen . Positive HIV , Hepatitis B surface antigen Hepatitis C antibody . Participating study within 30 day prior screen . Other medical psychiatric condition opinion investigator would place subject increase risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>